Advanced in Autoimmune Hemolytic Anemia

Dr. Arshad R. Shaikh

Hematology Oncology | Hospital Medicine | Hematology
Freeport Memorial Hospital
1163 W Stephenson St, 
Freeport, IL 
Accepting New Patients
Offers Telehealth
Advanced in Autoimmune Hemolytic Anemia
Freeport Memorial Hospital
1163 W Stephenson St, 
Freeport, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Arshad Shaikh is a Hematologist Oncology specialist and a Hospital Medicine provider in Freeport, Illinois. Dr. Shaikh is rated as an Advanced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Severe Congenital Neutropenia, Angiosarcoma, Inflammatory Breast Cancer, and Chronic Familial Neutropenia. Dr. Shaikh is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hospital Medicine
Hematology
Licenses
Internal Medicine in IL
Hospital Affiliations
Midwest Medical Center
Fhn Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MetLife
  • PPO
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

FREEPORT MEMORIAL HOSPITAL
1163 W Stephenson St, Freeport, IL 61032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
View 5 Less Clinical Trials

2 Total Publications

Unlocking the Potential of Sotagliflozin in Diabetes Mellitus targeting SGLT 1 & SGLT 2: A Comprehensive Review.
Unlocking the Potential of Sotagliflozin in Diabetes Mellitus targeting SGLT 1 & SGLT 2: A Comprehensive Review.
Journal: Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
Published: June 22, 2025
Similar Doctors
Advanced in Autoimmune Hemolytic Anemia
Dr. Eliot C. Williams
Hematology
Advanced in Autoimmune Hemolytic Anemia
Dr. Eliot C. Williams
Hematology

University Of Wisconsin Medical Foundation Inc

20 S Park St, 
Madison, WI 
 (54.7 miles away)
608-287-2076
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Eliot Williams is a Hematologist in Madison, Wisconsin. Dr. Williams is rated as an Advanced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Hemophilia B, Autoimmune Hemolytic Anemia, Polycythemia Vera, Essential Thrombocythemia, and Bone Marrow Aspiration. Dr. Williams is currently accepting new patients.

Advanced in Autoimmune Hemolytic Anemia
Dr. Mete Korkmaz
Oncology | Hematology
Advanced in Autoimmune Hemolytic Anemia
Dr. Mete Korkmaz
Oncology | Hematology

Osf Multi-Specialty Group

5666 E State St, 
Rockford, IL 
 (32.4 miles away)
815-921-8929
Languages Spoken:
English
See accepted insurances

Mete Korkmaz is an Oncologist and a Hematologist in Rockford, Illinois. Dr. Korkmaz is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Angiosarcoma, and Bone Marrow Aspiration.

Advanced in Autoimmune Hemolytic Anemia
Dr. Roy H. Kim
Hematology Oncology | Hematology
Advanced in Autoimmune Hemolytic Anemia
Dr. Roy H. Kim
Hematology Oncology | Hematology

Dean Health Systems Inc

1211 Fish Hatchery Rd, 
Madison, WI 
 (54.8 miles away)
608-252-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Roy Kim is a Hematologist Oncology specialist and a Hematologist in Madison, Wisconsin. Dr. Kim is rated as an Advanced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Pulmonary Embolism, Thrombocytopenia, Autoimmune Hemolytic Anemia, Anemia, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shaikh's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 19 Advanced Conditions
    View All 103 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile